Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.59
NAS:ZGNX's Cash-to-Debt is ranked higher than
53% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. NAS:ZGNX: 3.59 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ZGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 1.83 Max: N/A
Current: 3.59
Equity-to-Asset 0.48
NAS:ZGNX's Equity-to-Asset is ranked lower than
67% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NAS:ZGNX: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ZGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.87  Med: 0.18 Max: 0.61
Current: 0.48
-3.87
0.61
Piotroski F-Score: 2
Altman Z-Score: -1.95
Beneish M-Score: -4.16
WACC vs ROIC
15.48%
-150.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -356.78
NAS:ZGNX's Operating Margin % is ranked lower than
90% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. NAS:ZGNX: -356.78 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ZGNX' s Operating Margin % Range Over the Past 10 Years
Min: -356.78  Med: -175.58 Max: 142.89
Current: -356.78
-356.78
142.89
Net Margin % -360.90
NAS:ZGNX's Net Margin % is ranked lower than
90% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. NAS:ZGNX: -360.90 )
Ranked among companies with meaningful Net Margin % only.
NAS:ZGNX' s Net Margin % Range Over the Past 10 Years
Min: -360.9  Med: -223.29 Max: 96.18
Current: -360.9
-360.9
96.18
ROE % -58.04
NAS:ZGNX's ROE % is ranked lower than
86% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NAS:ZGNX: -58.04 )
Ranked among companies with meaningful ROE % only.
NAS:ZGNX' s ROE % Range Over the Past 10 Years
Min: -491.54  Med: -222.19 Max: 23.3
Current: -58.04
-491.54
23.3
ROA % -32.13
NAS:ZGNX's ROA % is ranked lower than
83% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. NAS:ZGNX: -32.13 )
Ranked among companies with meaningful ROA % only.
NAS:ZGNX' s ROA % Range Over the Past 10 Years
Min: -164.96  Med: -83.71 Max: 10.28
Current: -32.13
-164.96
10.28
ROC (Joel Greenblatt) % -460.41
NAS:ZGNX's ROC (Joel Greenblatt) % is ranked lower than
87% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. NAS:ZGNX: -460.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ZGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -508.05  Med: -389.19 Max: 547.3
Current: -460.41
-508.05
547.3
3-Year Revenue Growth Rate -21.80
NAS:ZGNX's 3-Year Revenue Growth Rate is ranked lower than
91% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. NAS:ZGNX: -21.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ZGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.45 Max: -21.8
Current: -21.8
3-Year EBITDA Growth Rate -6.00
NAS:ZGNX's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. NAS:ZGNX: -6.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ZGNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.1 Max: -6
Current: -6
3-Year EPS without NRI Growth Rate -19.70
NAS:ZGNX's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NAS:ZGNX: -19.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ZGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -66.4 Max: -19.7
Current: -19.7
GuruFocus has detected 5 Warning Signs with Zogenix Inc $NAS:ZGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ZGNX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ZGNX Guru Trades in Q1 2016

Paul Tudor Jones 16,400 sh (-1.28%)
Jim Simons 74,087 sh (-45.88%)
» More
Q2 2016

ZGNX Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Jim Simons 37,187 sh (-49.81%)
» More
Q3 2016

ZGNX Guru Trades in Q3 2016

Jim Simons 93,287 sh (+150.86%)
» More
Q4 2016

ZGNX Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NAS:RMTI, NAS:NBRV, OTCPK:ABSCF, NAS:ALIM, AMEX:NNVC, NAS:OASM, OTCPK:PXSLY, NAS:PRPH, NAS:TNXP, AMEX:AXN, NAS:IMNP, NAS:ALQA, NAS:NVGN, OTCPK:INNV, OTCPK:SUWN, NAS:RTRX, AMEX:CPHI, NAS:BSPM, OTCPK:ATHJF, OTCPK:ECTE » details
Traded in other countries:Z081.Germany,
Headquarter Location:USA
Zogenix Inc is a pharmaceutical company engaged in commercializing & developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.

Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Its trademarks include DosePro, Relday, Zogenix and Zohydro ER. The Company is subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Top Ranked Articles about Zogenix Inc

Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
EMERYVILLE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22, 2017, in New York, NY.
  Zogenix Presentation Details
Date:Wednesday, March 22, 2017Time:2:10 pm Eastern Time / 11:10 am Pacific TimeLocation:New York, NY - Westin New York Grand Central Hotel  The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.                                  About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]

Read more...
Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9

EMERYVILLE, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2016, after the market close, and will host a corporate update conference call and webcast on Thursday, March 9th, at 4:30 PM Eastern Time.
 Thursday, March 9th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Toll Free:877-675-4750International:719-325-4867Conference ID:1061121Webcast:http://public.viavid.com/index.php?id=122985  Replays, available through March 23, 2017:
Domestic:844-512-2921International:412-317-6671Replay PIN:1061121  About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]

Read more...
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome

EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European Commission (EC) has designated ZX008 (fenfluramine) as an orphan medicinal product for the treatment of Lennox Gastaut Syndrome (LGS), a refractory, debilitating childhood-onset epilepsy. The EC’s approval follows a positive opinion in January from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
“This Orphan Drug Designation is an important component in our strategy to evaluate potential expanded uses of ZX008 in other rare and severe epilepsy conditions,” said Stephen J. Farr, Ph.D., President and Chief Executive Officer of Zogenix.  “Compelling preliminary efficacy data from an on-going, open-label Phase 2 study for ZX008 in LGS were presented in December 2016 at the American Epilepsy Society Annual Meeting. Based on these promising results, we intend to move forward with a Phase 3 clinical study for ZX008 in LGS in the second half of 2017.” Orphan Drug Designation is granted by the EC to drugs that are intended for the treatment of life-threatening or chronically debilitating, rare diseases where no satisfactory treatment of the condition concerned is authorized. If such a treatment exists, then the medicine must be of significant benefit to those affected by the condition. Rare diseases are those defined as having a prevalence of not more than five per 10,000 population in Europe. The Orphan Drug Designation provides potential incentives for the sponsor from the European Union to develop a medicine for a rare disease, such as protocol assistance, reduced fees, funding from the EC for clinical trials and protection from competition once the medicine is placed on the market, including ten years of market exclusivity. Zogenix is currently enrolling patients in the U.S. and internationally for a ZX008 Phase 3 program in Dravet syndrome, another intractable, severe epilepsy that begins in infancy. ZX008 is designated as an orphan drug in both the U.S. and Europe, and it also received Fast Track designation in the U.S. for the treatment of Dravet syndrome. About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. For more information, visit www.zogenix.com. Forward Looking Statements
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the potential commercialization of ZX008; ZX008’s potential as a treatment for seizures associated with LGS; the enrollment of patients in the on-going Phase 3 clinical trials of ZX008 for patients with Dravet syndrome; the continued evaluation of patients in the open-label Phase 2 clinical trial of ZX008 for patients with LGS and the timing of the launch of a Phase 3 program for LGS. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix's business, including, without limitation: risks that the benefits associated with orphan drug designation may not be realized, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained; the uncertainties associated with the clinical development and regulatory approval of product candidates such as ZX008, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies may not be predictive of future results; Zogenix's reliance on third parties to conduct its clinical trials, enroll patients, manufacture its preclinical and clinical drug supplies and manufacture commercial supplies of its drug products, if approved; unexpected adverse side effects or inadequate therapeutic efficacy of ZX008 that could limit approval and/or commercialization, or that could result in recalls or product liability claims; Zogenix's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; Fast Track designation may not result in an expedited regulatory review process; the potential for distraction of management related to the transition of management responsibilities; and other risks described in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.15
ZGNX's PB Ratio is ranked higher than
63% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. ZGNX: 3.15 )
Ranked among companies with meaningful PB Ratio only.
ZGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.15  Med: 3.82 Max: 543.53
Current: 3.15
1.15
543.53
PS Ratio 14.07
ZGNX's PS Ratio is ranked lower than
80% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ZGNX: 14.07 )
Ranked among companies with meaningful PS Ratio only.
ZGNX' s PS Ratio Range Over the Past 10 Years
Min: 0.35  Med: 6.32 Max: 15.46
Current: 14.07
0.35
15.46
EV-to-EBIT -3.45
ZGNX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. ZGNX: -3.45 )
Ranked among companies with meaningful EV-to-EBIT only.
ZGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.8  Med: -2.8 Max: 5
Current: -3.45
-19.8
5
EV-to-EBITDA -3.52
ZGNX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. ZGNX: -3.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.1  Med: -2.8 Max: 4.9
Current: -3.52
-21.1
4.9
Current Ratio 5.39
ZGNX's Current Ratio is ranked higher than
80% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. ZGNX: 5.39 )
Ranked among companies with meaningful Current Ratio only.
ZGNX' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.85 Max: 10.58
Current: 5.39
0.85
10.58
Quick Ratio 4.89
ZGNX's Quick Ratio is ranked higher than
81% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. ZGNX: 4.89 )
Ranked among companies with meaningful Quick Ratio only.
ZGNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.5 Max: 9.74
Current: 4.89
0.32
9.74
Days Inventory 200.35
ZGNX's Days Inventory is ranked lower than
72% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. ZGNX: 200.35 )
Ranked among companies with meaningful Days Inventory only.
ZGNX' s Days Inventory Range Over the Past 10 Years
Min: 154.96  Med: 193.2 Max: 419.33
Current: 200.35
154.96
419.33
Days Sales Outstanding 16.78
ZGNX's Days Sales Outstanding is ranked lower than
87% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. ZGNX: 16.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.78  Med: 69.66 Max: 159.12
Current: 16.78
16.78
159.12
Days Payable 56.10
ZGNX's Days Payable is ranked higher than
54% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. ZGNX: 56.10 )
Ranked among companies with meaningful Days Payable only.
ZGNX' s Days Payable Range Over the Past 10 Years
Min: 56.1  Med: 85.06 Max: 148.78
Current: 56.1
56.1
148.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.60
ZGNX's 3-Year Average Share Buyback Ratio is ranked lower than
74% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. ZGNX: -12.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -348.1  Med: -29.1 Max: 0
Current: -12.6
-348.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 2.22
ZGNX's Price-to-Median-PS-Value is ranked lower than
75% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ZGNX: 2.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.89 Max: 2.3
Current: 2.22
0.07
2.3
Earnings Yield (Greenblatt) % -28.82
ZGNX's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. ZGNX: -28.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -29.11  Med: 37.3 Max: 69.3
Current: -28.82
-29.11
69.3

More Statistics

Revenue (TTM) (Mil) $22.34
EPS (TTM) $ -3.25
Beta2.26
Short Percentage of Float18.53%
52-Week Range $7.33 - 13.83
Shares Outstanding (Mil)24.81

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 34 61
EPS ($) -4.79 -1.37
EPS without NRI ($) -4.79 -1.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results May 04 2017 
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome Apr 27 2017 
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May Apr 27 2017 
Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference Mar 15 2017 
Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Mar 02 2017 
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome Mar 01 2017 
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of... May 22 2017
ETFs with exposure to Zogenix, Inc. : May 11, 2017 May 11 2017
Edited Transcript of ZGNX earnings conference call or presentation 4-May-17 8:30pm GMT May 11 2017
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Zogenix reports 1Q loss May 04 2017
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results May 04 2017
Investor Network: Zogenix, Inc. to Host Earnings Call May 04 2017
Blog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome May 01 2017
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome Apr 27 2017
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May... Apr 27 2017
ETFs with exposure to Zogenix, Inc. : April 17, 2017 Apr 17 2017
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference Mar 15 2017
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results Mar 09 2017
Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and... Mar 02 2017
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)